Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.43 +0.17 (+0.41%)
Streaming Delayed Price Updated: 10:31 AM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 315,408
Open 41.10
Bid (Size) 41.40 (400)
Ask (Size) 41.44 (100)
Prev. Close 41.26
Today's Range 41.10 - 41.62
52wk Range 32.38 - 49.62
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Best Healthcare Stocks to Buy With $50 Right Now ↗
Even on a budget, you can get quality stocks. 
Via The Motley Fool
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit

Performance

YTD
-4.9%
-4.9%
1 Month
-6.0%
-6.0%
3 Month
-2.7%
-2.7%
6 Month
+2.4%
+2.4%
1 Year
+11.8%
+11.8%

More News

Read More
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Exelixis Inc. (NASDAQ:EXEL) Stands Out as a Quality Investing Candidate ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
Via Chartmill
News headline image
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗
Via MarketBeat
News headline image
Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
Via Chartmill
News headline image
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
2 Stocks That Could Soar This Year ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
From Exelixis, Inc.
Via Business Wire
News headline image
2 Healthcare Stocks to Buy for 2026 and Beyond ↗
Via The Motley Fool
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗
Via Chartmill
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
From Equity Insider
Via GlobeNewswire

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 41.43
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 03/20/26 10:31 AM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 13.05B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.